Nav: Home

Healthy cells 'collaborate' with tumors to help build new blood vessels

March 03, 2016

Healthy cells actively collaborate with tumours by creating a mesh of collagen that encourages cancer cells to build new blood vessels, a new study shows.

Researchers found that 'collaborator' cells build a beneficial environment around the tumour which helps it to build the new blood vessels it needs to grow.

Scientists at The Institute of Cancer Research, London, and the Cancer Research UK Beatson Institute in Glasgow, showed that a type of signal called transfer RNA plays a key role in driving collagen production to increase the blood supply to tumours.

Their study sheds light on the key role played by the surrounding environment in a tumour's growth and development - and could open up novel approaches to treatment.

It is published today (Thursday) in Current Biology and was funded by organisations including Cancer Research UK and Breast Cancer Now.

Cells called fibroblasts are the body's natural factories for collagen, the main structural protein of the body. In most healthy tissues, fibroblasts mainly generate type I collagen.

But researchers found that fibroblasts near tumours switch from producing type I collagen to type II collagen. They showed that this change in collagen production helps the tumour to build new blood vessels - supporting its growth.

The researchers found that fibroblast cells that were activated by malignant breast tumours produced much more of a type of transfer RNA called the initiator methionine tRNA, than they would normally. The increase in this particular transfer RNA allowed fibroblasts to increase their production of type II collagen.

The initiator methionine tRNA is required for all protein production in the cell, so it might be expected that increased levels of it would raise levels of all cellular proteins. However, the researchers showed that increased levels of the transfer RNA resulted in increased levels of specific proteins only, including collagen II.

The work therefore reveals an unexpected role for the initiator methionine tRNA in controlling production of secreted collagens that promote blood vessel growth in tumours.

Study co-leader Dr Andrew Reynolds, Leader of the Tumour Biology Team at The Institute of Cancer Research, London, said:

"Cancers can't gather together the resources they need to grow and spread all by themselves - they need the support of surrounding healthy cells. Our study shows that a specific type of transfer RNA can ramp up production of collagen II protein in fibroblasts, stimulating the blood vessel growth in tumours that promotes cancer growth. Our results could open up new approaches to treatment, such as drugs that are designed to disrupt cancer's ability to manipulate its environment."

Study co-leader Professor Jim Norman, Leader of the Integrin Cell Biology Laboratory at the Cancer Research UK Beatson Institute, Glasgow, said:

"It is known that cancers have alterations to their repertoire of transfer RNAs - in particular they display elevated levels of the initiator methionine tRNA. Our study is important because it shows that this does not lead directly to increased synthesis of cellular protein to make more cells - as had previously been suggested - but very selectively alters production of certain secreted proteins, such as collagen II. This then indirectly drives tumour growth by helping the tumour solicit its own blood supply."

Dr Laura McCallum, Cancer Research UK's Senior Research Information Manager, said:

"This exciting study adds to the growing evidence that no cancer cell acts alone. Understanding how cancer cells manipulate healthy neighbouring cells to support them is vital if we are to find new ways to stop the disease in its tracks."

Dr Richard Berks, Senior Research Communications Officer at Breast Cancer Now, said:

"This early study highlights one way that normal cells could be helping tumours grow and spread, by promoting the growth of new blood vessels.

"We know tumours cannot exist in isolation; they must recruit non-cancer cells in their local environment to help them progress and researchers are now trying to understand whether this relationship could provide an effective target for treatments.

"Improving our understanding of the tumour micro-environment, and how it helps tumours to grow, will be critical to finding ways to stop breast and other cancers. We look forward to further discoveries in this area in the future."
-end-
For more information please contact the ICR press office on 020 7153 5582 / henry.french@icr.ac.uk. For enquiries out of office hours, please call 07595 963613.

Notes to editors

The Institute of Cancer Research, London, is one of the world's most influential cancer research institutes.

Scientists and clinicians at The Institute of Cancer Research (ICR) are working every day to make a real impact on cancer patients' lives. Through its unique partnership with The Royal Marsden Hospital and 'bench-to-bedside' approach, the ICR is able to create and deliver results in a way that other institutions cannot. Together the two organisations are rated in the top four cancer centres globally.

The ICR has an outstanding record of achievement dating back more than 100 years. It provided the first convincing evidence that DNA damage is the basic cause of cancer, laying the foundation for the now universally accepted idea that cancer is a genetic disease. Today it leads the world at isolating cancer-related genes and discovering new targeted drugs for personalised cancer treatment.

As a college of the University of London, the ICR provides postgraduate higher education of international distinction. It has charitable status and relies on support from partner organisations, charities and the general public.

The ICR's mission is to make the discoveries that defeat cancer. For more information visit http://www.icr.ac.uk

About the Beatson Institute for Cancer Research

The Beatson Institute for Cancer Research is core-funded by Cancer Research UK and provides a dynamic, supportive and well-resourced environment for its basic and translational scientists. Its mission is to:
  • Understand how cancer cells grow, survive and spread
  • Identify critical components of these pathways as targets for novel cancer treatments
  • Help translate this knowledge for the benefit of cancer patients
At the beginning of 2008 the Beatson Institute moved into a new state-of-the -art building - further information can be found at http://www.beatson.gla.ac.uk

About Cancer Research UK

  • Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
  • Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
  • Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
  • Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last forty years.
  • Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that 3 in 4 people will survive their cancer for at least 10 years within the next 20 years.
  • Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
  • Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit http://www.cancerresearchuk.org.

Institute of Cancer Research

Related Breast Cancer Articles:

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.
Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.
Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.
More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.
Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.
Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.
Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.
Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.
Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.
Does MRI plus mammography improve detection of new breast cancer after breast conservation therapy?
A new article published by JAMA Oncology compares outcomes for combined mammography and MRI or ultrasonography screenings for new breast cancers in women who have previously undergone breast conservation surgery and radiotherapy for breast cancer initially diagnosed at 50 or younger.
More Breast Cancer News and Breast Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Climate Mindset
In the past few months, human beings have come together to fight a global threat. This hour, TED speakers explore how our response can be the catalyst to fight another global crisis: climate change. Guests include political strategist Tom Rivett-Carnac, diplomat Christiana Figueres, climate justice activist Xiye Bastida, and writer, illustrator, and artist Oliver Jeffers.
Now Playing: Science for the People

#562 Superbug to Bedside
By now we're all good and scared about antibiotic resistance, one of the many things coming to get us all. But there's good news, sort of. News antibiotics are coming out! How do they get tested? What does that kind of a trial look like and how does it happen? Host Bethany Brookeshire talks with Matt McCarthy, author of "Superbugs: The Race to Stop an Epidemic", about the ins and outs of testing a new antibiotic in the hospital.
Now Playing: Radiolab

Speedy Beet
There are few musical moments more well-worn than the first four notes of Beethoven's Fifth Symphony. But in this short, we find out that Beethoven might have made a last-ditch effort to keep his music from ever feeling familiar, to keep pushing his listeners to a kind of psychological limit. Big thanks to our Brooklyn Philharmonic musicians: Deborah Buck and Suzy Perelman on violin, Arash Amini on cello, and Ah Ling Neu on viola. And check out The First Four Notes, Matthew Guerrieri's book on Beethoven's Fifth. Support Radiolab today at Radiolab.org/donate.